Integrated Drug Discovery RG Discovery combines drug discovery and analytical chemistry capabilities, presenting a cross-selling opportunity to clients seeking end-to-end small molecule programs, from hit finding to clinical candidates, including fragment-based approaches.

Strategic Partnerships Recent collaborations with PolyPeptide Group and Desupervised AI partnerships indicate RG Discovery’s openness to co-development and AI-augmented workflows, suggesting potential for joint ventures or channel partnerships to expand service offerings.

Regional Expertise Based in Lund within the Medicon Valley, RG Discovery is well-positioned to engage Nordic biotech clusters and academic collaborations, enabling local business development, grant-funded programs, and pilot projects with nearby biotech startups.

Growth via Acquisition Pelago Bioscience AB’s acquisition of RG Discovery signals a potential for expanded capabilities and customer reach; sales teams can target clients of both entities with integrated biology and chemistry solutions.

Niche Specialization Focus on small molecules, macrocycles and peptides with advanced analytics, MS and NMR capabilities creates a differentiated value proposition for biotech clients needing specialized analytical depth and synthesis capabilities.